Learn how AbbVie could help you save on IMBRUVICA®. Call 1-866-IMBRUVICA or click to learn more >

IMBRUVICA® has helped many adults with CLL/SLL live longer

In a clinical trial of 269 people, 8% of CLL patients on IMBRUVICA® (ibrutinib) died versus 16% taking a chemotherapy (chlorambucil), after 28 months of follow-up.1*

Here’s to more time together and the opportunity to keep doing what you love.

Here’s to the life in your years

Here’s to saving on IMBRUVICA®

You may pay as little as $0 per prescription with the IMBRUVICA® Copay Card. Subject to eligibility; restrictions apply.†

Enroll Now

Receive one-on-one support plus financial and educational resources to help start and stay on track with IMBRUVICA®‡

Explore Support Options

IMBRUVICA® is approved for multiple uses. Choose from below:

CLL/SLLAdults with Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaWMAdults with Waldenström's MacroglobulinemiacGVHDPreviously Treated Chronic Graft Versus Host Disease in Adults and Children

*In a clinical study of 269 people aged 65 and older with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had not been treated before, people who took IMBRUVICA® had a 56% lower risk of death compared to those taking a chemotherapy (chlorambucil). With a median follow-up of approximately 28 months, 8% of IMBRUVICA® patients died compared to 16% taking a chemotherapy.

A treatment option that isn't chemotherapy

IMBRUVICA® is an oral, once-daily medicine that works differently from chemotherapy.

Learn More About How IMBRUVICA® Works

Coverage and cost questions?

Understand your insurance coverage and potential financial support options.

Explore Coverage and Cost Options

Discover personalized one-on-one support

Get support when you need it with help from IMBRUVICA® By Your Side Ambassadors and communications.‡

Explore Support Options

Learn from a patient

Real CLL patients tell personal stories about their experience with IMBRUVICA®.

View Patient Videos

†Eligibility: Available to patients with commercial insurance coverage for IMBRUVICA® (ibrutinib) who meet eligibility criteria. This copay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit https://www.imbruvica.com/imbruvica-by-your-side or call 1-888-968-7743 for additional information. For information on how we collect and process your personal data, including the categories we collect, purposes for their collection, and disclosures to third parties, visit https://www.pharmacyclics.com/privacy-notice.html#info_pcp.

‡IMBRUVICA® By Your Side patient support program is not intended to provide medical advice, replace prescribed treatment plans, or provide treatment or case management services. Patients are advised to talk to their healthcare provider and treatment team about any medical decisions and concerns they may have. By Your Side Ambassadors are provided by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie Company, and do not work under the direction of your healthcare professional (HCP) or give medical advice. They are trained to direct patients to their HCP for treatment-related advice, including further referrals.

Reference: 1. IMBRUVICA® (ibrutinib) Prescribing Information.